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Atopic dermatitis (AD) is a common skin condition that is characterized by a complex, heterogeneous
pathogenesis. The possible candidates for its pathogenesis include skin barrier abnormality and allergy/
immunology aspects. It has long been asked, “Which comes ﬁrst, the barrier dysfunction or the allergy/
immunology abnormality?” Recently, direct evidence of a link between the incidence of AD and loss-of-
function mutations in the gene encoding Filaggrin has been discovered. This ﬁnding suggests that barrier
dysfunction is a primary cause of AD. It has also been widely recognized that T cells play an important
role in the development of AD in the perspective of the Th1/Th2 paradigm. Recently, however, new T cell
subsets, Th17, T22, and regulatory T cells have been identiﬁed. In this review, wewill update the roles of T
cell subsets in AD and ascertain how skin barrier abnormality and allergy/immunology interact in
a highly interdisciplinary manner.
Copyright  2012, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Atopic dermatitis (AD) is a relapsing chronic inﬂammatory skin
disease characterized by eczematous skin lesions and intense
pruritus.1 AD is one of the most frequent chronic inﬂammatory
skin diseases and is increasingly prevalent, affecting at least 15%
of children and 2e10% of adults in industrialized countries.2 The
skin is an active organ of the immune system and can, therefore,
inﬂuence systemic immunity3; consequently, patients with AD
often have other allergic disorders, such as food allergy, asthma,
and allergic rhinitis,2 which is called allergic (or atopic) march
(Figure 1).4 Therefore, it is important to evaluate the mechanism
of AD. Thus far, the pathogenesis of AD has been attributed to
a complex interaction among the environment and host suscep-
tibility genes, altered skin barrier function and the immune
system.5 In this review, we will focus on the role of barrier
functions and immune systems, especially in line with helper T
(Th) cell subsets and regulatory T cells (Treg), in the development
of AD.duate School of Medicine, 54
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Outermost barriers are critical to avoid desiccation and to protect
us from insult from foreign bodies. Mammalian skin consists of two
sets of barriers: the stratum corneum and tight junctions (TJs). Thus
far, several causes of xerosis have been considered: (i) a decrease in
skin ceramides6; (ii) alterations of the stratum corneum pH7; (iii)
overexpression of the proteases, including kallikreins (KLKs) and
chymases8; and (iv) defects in Filaggrin (FLG). 9
In Netherton syndrome, unregulated pH-sensitive KLK5 directly
activates proteinase-activated receptor 2 and induces nuclear factor
kappaB-mediated overexpression of thymic stromal lymphopoietin
(TSLP), which aggravates AD-like skin lesions.10
The role of TJ in AD remains unknown. A knockout study of
claudin-1, a TJ-speciﬁc integral membrane protein, demonstrated
that TJs function as paracellular diffusion barriers in mammalian
epidermis.11 In humans, lack of claudin-1 lead to ichthyosis with
scalp hypotrichosis, scarring alopecia, neonatal sclerosing chol-
angitis, and leukocyte vacuolization (NISCH syndrome),12 but
a precise description in terms of skin manifestation has not been
provided, especially in relation to AD.
One of the characteristics of AD is dry skin that affects both
lesional and non-lesional skin areas.1 Dry skin in AD is in accord
with increased transepidermal water loss, which suggests that the
skin barrier is disrupted in AD. It has long been thought that then. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 Allergic march. The allergic march is characterized by a typical sequence of
sensitization and manifestation of symptoms that appear during a certain age period,
persist over years or decades, and often show a tendency for spontaneous remission
with age.
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rather the initiator of its pathogenesis.13 As a result of the barrier
disruption, the skin may permit the penetration of external stimuli,
such as allergens, bacteria, and viruses.14Role of Filaggrin in skin barrier
The direct evidence for a primary structural abnormality of the
stratum corneum in AD is a recently discovered link between the
incidence of AD and loss-of-function mutations in the gene
encoding FLG. Individuals carrying the FLG null allele variants tend
to develop AD.9 FLG protein is localized in the granular layers of the
epidermis (Figure 2). Proﬁlaggrin, a 400-kDa polyprotein, is the
main component of keratohyalin granules.15,16 In the differentiation
of keratinocytes, proﬁlaggrin is dephosphorylated and cleaved into
10e12 FLG molecules (a molecular mass of 37 kDa in human and
27 kDa in mice), which aggregates in the keratin cytoskeleton
system to form a dense protein-lipid matrix in humans.15 These FLG
monomers are further degraded into natural moisturizing factors
by either caspase 14 or bleomycin hydrolase, which are important
for maintaining hydration and keeping the skin pH low (Figure 2).
Intriguingly, it has recently been reported that intragenic copyFigure 2 Role of Filaggrin. FLG protein is localized in the granular layers of the epidermis.
keratinocytes, proﬁlaggrin is dephosphorylated and cleaved into 10-12 FLG molecules, whic
These FLG monomers are further degraded into natural moisturizing factors, which are imnumber variation (20e24 copies in one person) within a FLG gene
contributes to the risk of AD with a dose-dependent effect.17
Flaky tail (Flgft) mice, essentially deﬁcient in Filaggrin, have been
used to investigate the role of Filaggrin in AD.18 There have been
four recent studies using Flgft mice as a model of Filaggrin deﬁ-
ciency: Fallon et al19 used Flgft mice from which the ma mutation
had been eliminated with four additional backcrosses to B6 mice,
and others used commercially available Flgft mice.20e22
The ﬁrst report showed only a histological abnormality without
clinical manifestations,19 the second report demonstrated sponta-
neous eczematous skin lesions after 28 weeks of age,20 the third
report did not indicate any spontaneous dermatitis in Flgft mice,21
and the fourth report observed spontaneous dermatitis as early
as 5 weeks of age, with gradual exacerbation with age.22 Humans
and mice differ in this respect, since most AD resolves with age in
humans and the cutaneous manifestations occurred only in
homozygous Flgft mice. The discrepancies between these results
seem to be related to the presence or absence of the ma mutation,
variation in the genetic backgrounds of each mouse strain, and
environmental factors.
Human AD can be categorized into the extrinsic and intrinsic
types. Extrinsic or allergic AD shows high total serum IgE levels and
the presence of speciﬁc IgE for environmental and food allergens,
whereas intrinsic or non-allergic AD exhibits normal total IgE
values and the absence of speciﬁc IgE.23 The skin barrier is per-
turbed in the extrinsic, but not the intrinsic, type. FLG gene muta-
tions are not a feature of extrinsic, but not intrinsic, AD.24Dendritic cells as an initiator for skin immune responses
Dendritic cells (DCs) play an important role in the initiation of
acquired immune responses. In the skin, there exist two pop-
ulations of DCs; epidermal Langerhans cells (LCs), and dermal DCs.
According to their expression of Langerin, dermal DCs are divided
into at least two populations: Langerin-positive dermal DCs and
Langerin-negative dermal DCs.25e27 LCs have long been regarded as
essential antigen presenting cells for the establishment of sensiti-
zation in hapten induced-contact hypersensitivity, but this concept
is now being challenged by recent analyses using LC ablation
murine models.28 Langerin-negative DCs play a major role in theProﬁlaggrin is the main component of keratohyaline granules. In the differentiation of
h aggregates in the keratin cytoskeleton system to form a dense protein-lipid matrix.
portant to maintain hydration and keep the skin pH low.
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Figure 3 Scheme on the development of AD. As shown in the ﬁgure, both barrier and
allergy/immunology play an important role in the development of AD in a highly
interdisciplinary manner.
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positive dermal DCs play a compensatory role.29
Conversely to hapten, which is a contact sensitizer that is small
enough to penetrate into the dermis of the skin, allergens for AD are
rather large. Therefore, LCs are thought to be the DCs responsible
for the acquisition of cutaneous allergens, such as house dust and
mites, in the development of AD. It has been demonstrated that
activation-induced LCs elongate their dendrites to penetrate tight
junctions and monitor the extra-tight junction environment
located outside of the tight junction barrier.30
Consistent with the above ﬁnding, in a mouse model of AD
induced by a vitamin D3 analogue, epidermal LC-depleted mice
treated with vitamin D3 did not exhibit either AD-like inﬂamma-
tion or increased serum IgE, as compared to control mice treated
with the vitamin D3 analogue.31 Overexpression of TSLP by kera-
tinocytes results in an AD-like inﬂammatory phenotype in mice,32
and TSLP is highly expressed in the epidermis of AD patients.33 In
addition, by applying an LC ablation system, it has recently been
reported that LCs are crucial for Th2 induction and IgE production
through TSLP signaling upon epicutaneous protein exposure.34
These results demonstrate that LCs are required for the develop-
ment of AD in mouse models of AD through epidermal TSLP
overexpression.31
Th1eTh2 paradigm in AD
AD has been considered the paradigm of an allergic Th2-mediated
disease, which is characterized by abnormal IgE production,
peripheral eosinophilia, mast cell activation, and induction of Th2
lymphocytes expressing interleukin (IL)-4, IL-10, and IL-13.1
Consistently, in mice, it has been established that repeated
application of hapten (2,4,6-trinitrochlorobenzene; TNCB) induces
AD-like skin lesions.35 In thismodel,whilst a single challenge induces
contact hypersensitivity, a prototype of delayed-type hypersensi-
tivity, repeated hapten application results in a shift fromTh1- toTh2-
mediated cutaneous inﬂammation, with elevated IL-4 expression,
eosinophil inﬁltration in the skin, and elevated hapten-speciﬁc
serum IgE levels.35 In addition, extraordinary sustained interferon
(IFN)-g expression leads to a Th1-dominant state in the mouse AD
model, with clinical amelioration of AD symptoms.36
It is known that epicutaneous application of protein antigen,
ovalbumin (OVA), induces a rise in OVA-speciﬁc serum IgE and
IgG1, both of which are induced in a Th2-dependent manner, as
well as the development of dermatitis, characterized by the inﬁl-
tration of CD3þ T cells, eosinophils, and neutrophils and local
expression of mRNA for the cytokines IL-4, IL-5, and, intriguingly,
IFN-g.37 Consistently, chronic exposure to protein antigens, espe-
cially those with protease activities, such as house dust mite
allergens, induces TSLP expression in the epidermis. The above
ﬁndings suggest that chronic exposures to either hapten or protein
antigen induce AD-like skin lesions inmice, which ﬁts well with the
pathogenesis of human AD (Figure 3).
By contrast, in a patch test, sequential biopsies in AD patients
exposed to aeroallergens, such as house dust mite, demonstrated
a biphasic immunologic response characterized by a switch from
a Th2 toward a Th1 phenotype in later phases of the disease.38 It
remains unknown how a Th1 shift occurs in the clinical setting. The
Th2 environment is known to inhibit the production of antimicrobial
peptides in the skin, which predispose the skin to superimposed
infection.39 Therefore, one possible explanation for Th2 to Th1
shifting in the chronic phase of AD is that superimposed infection of
Staphylococcus aureus shifts the skin condition towards Th1. Intrigu-
ingly, microbial colonization by S aureus ampliﬁes inﬂammation, and
further stresses the barrier in AD. It is important to address the role of
Th1 shifting in the pathogenesis of AD in the future.Th17 in the development of AD
In addition to the Th1/Th2 paradigm, the roles of Th17 and regu-
latory T cells (Treg) have been highlighted.40e43 Transforming
growth factor (TGF)-b, IL-1b, IL-6, and IL-23 are key factors involved
in naive T cell commitment to a Th17 phenotype. Th17 cells are
characterized by the production of inﬂammatory cytokines such as
IL-17A, IL-17F, IL-22, and IL-26. Th17 cells have been implicated in
several human autoimmune diseases, including multiple sclerosis,
rheumatoid arthritis, inﬂammatory bowel disease, and psoriasis.44
Epicutaneous immunization in mice with ovalbumin can cause
allergic skin inﬂammationresemblingAD, cutaneousexpressionof IL-
17A and IL-17F mRNA, and, subsequently, airway inﬂammation45
(Figure 3). In addition, the presence of Th17 cells and IL-17 in AD
patients has been demonstrated. Phenotypic analysis of peripheral
bloodmononuclearcellsderived fromADpatientsexhibitedamarked
increase in the IL-17þCD4þ T-cell population. The high percentage of
IL-17-producing cells was found in severe AD,46,47 which suggests
a direct correlation between the presence of Th17 cells and the
severity of the disease. Increased levels of IL-17 were also reported in
cutaneous lesions of AD patients. Consistently, Flgftmicewere shown
to possess increased IL-17 mRNA levels in skin lesions shortly after
epicutaneous application of OVA.20 It has been demonstrated that IL-
17A and IL-17F promote eosinophil production of CXCL1, IL-8, and
CCL4, as well as IL-1b and IL-6, indicating that there is possible cross-
talk between Th17 cells and eosinophils in AD.48
By contrast, distinct IL-22-producing CD4þ and CD8þ T-cell
populations (called T22) were signiﬁcantly increased in AD skin. IL-
22þCD8þ T-cell frequency correlated with AD disease severity.49
Therefore, the above ﬁndings suggest that a Th2/T22 polarization
dominates chronic AD. CCL27, the ligand for CCR10, is highly
expressed in skin lesions from AD patients,50 and, combined with
the recent ﬁnding that T22 cells particularly express CCR10, this
might be an explanation for the increased presence of T22 in
chronic AD skin. IL-22 has been shown to induce acanthosis and
hypogranulosis in skin by downregulation of genes involved in
terminal differentiation of the skin,51 which may be involved in the
development of AD (Figure 3).
Treg in the suppressor for AD
Treg exist in all non-lymphoid tissues, and the skin is one of the
tissues that has a high proportion of Treg in the steady state in
both mice and humans.43,52,53 Treg in the skin are CD44þ and
CD103high 43,52,53, and they express chemokine receptors, CCR4,
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cutaneous lesions of Leishmania major infection.54 Mice with
a complete loss of CCR4 on Treg develop spontaneous lymphocytic
inﬁltration and severe inﬂammation in the skin and lungs,
accompanied by peripheral lymphadenopathy and increased
differentiation of skin tropic CD4þFoxp3memory T cells. Using a-
1, 3-fucosyltransferase VII (Fut7) deﬁcient mice, Dudda et al have
reported the importance of E- and P-selectin ligands for Treg
migration to the skin.53 Loss of the bindings of selectins caused
skin speciﬁc inﬂammation, indicating the essential role of skin-
resident Treg for maintaining immune homeostasis locally.
In addition, it has also been reported that Treg is accumulated in
the skin during contact hypersensitivity43 and that IL-10 is induced
in the repeat hapten application-induced chronic contact hyper-
sensitivity model,55 indicating that chronic antigen exposure
induces Treg accumulation into the skin (Figure 3).
From observation of patients with IPEX syndrome (immuno-
dysregulation polyendocrinopathy enteropathy X-linked
syndrome) who show atopic-like dermatitis and high IgE levels as
well as loss of Treg functions, it appears likely that Treg is related to
the development of AD lesion.56 AD patients have a higher number
of Treg in peripheral blood with comparable suppressive
activity57,58 and expansion of Treg has been positively associated
with disease activity in AD.59 On the contrary, it has also been re-
ported that the numbers of Treg in peripheral blood are similar in
both AD patients and healthy controls.60 Although it was initially
reported that Treg were absent in the AD skin lesion, whereas Tr1
were detected,61 several groups later reported the existence of Treg
in the skin lesion of AD.62,63 Reefer et al, however, reported that
a new subtype of Treg with Th2 promoting ability was observed in
AD and that its functions depended on the expression of CCR6.64 AD
is a chronic inﬂammatory disease that has multiple disease stages,
and treatments for AD, such as cyclosporine,58,60,65 glucocoritoid,66
and UV67 can alter the number of Treg in the blood. Therefore, the
interpretation and comparison of each study need careful attention.
Barrier and allergy/immunology interplay in the development
of AD
It has been investigated whether acute removal of stratum cor-
neum modulates the production of cytokines and chemokines by
epidermal cells. Tape stripping upregulates TSLP levels in the skin,
which polarizes skin DCs to elicit a Th2 response via the induction
of IL-10.68 Therefore, barrier disruption itself seems to shift the skin
environment towards Th2. In addition, Th2 chemokines (CCL17 and
CCL22) and eosinophil chemoattractant (CCL5) mRNA levels were
remarkably elevated in mice by barrier disruption, which was
augmented by tape-stripping more markedly than by acetone-
rubbing.69 Furthermore, tape stripping induced dermal inﬁltration
of eosinophils in mice.69 These ﬁndings suggest that acute barrier
removal induces the expression of Th2 and eosinophil chemokines
by epidermal cells and easily evokes the late phase reaction upon
challenge with antigen. This indicates that the barrier dysfunction
predisposes the skin environment to Th2 skewing conditions as
well as the feasibility for antigen exposure to the internal skin
(Figure 3). Therefore, this conclusion answers the initial question,
“Which comes ﬁrst, the chicken or the egg?” Under certain condi-
tions, especially when the Filaggrin is mutated or scratching
disrupts the skin barrier, the barrier dysfunction is the primary
cause of the development of AD.
Intriguingly, by contrast, human keratinocytes differentiated in
the presence of IL-4 and IL-13 exhibited signiﬁcantly reduced FLG
geneexpression.70 In addition, IL-17Adownregulates the expression
of Filaggrin and genes important for cellular adhesion, which leads
to the impairment of epidermal barrier formation.71 Consistently,the level of FLG expression in AD patients, even those without FLG
mutations, was decreased. These ﬁndings indicate that the atopic
inﬂammatory response can induce an acquired barrier defect and
that these create a positive feedback loop by interplaying in a highly
interdisciplinary manner in the development of AD.Declaration of all sources of funding
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